A Phase II Trial of Androgen Deprivation, Docetaxel and Enzalutamide in Patients With Metastatic Hormone Sensitive Prostate Cancer
Latest Information Update: 24 Sep 2023
At a glance
- Drugs Docetaxel (Primary) ; Enzalutamide (Primary) ; Antiandrogens
- Indications Adenocarcinoma; Bone metastases; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms ENZADA
- 06 Jun 2023 Results (at data cut-off: 9 Feb 2022) reporting efficacy and safety at median follow up 42.6 months presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 07 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 14 May 2021 Planned End Date changed from 1 Mar 2027 to 1 Mar 2028.